SG10201601731RA - Piperazine-substituted benzothiophene derivatives as antipsychotic agents - Google Patents
Piperazine-substituted benzothiophene derivatives as antipsychotic agentsInfo
- Publication number
- SG10201601731RA SG10201601731RA SG10201601731RA SG10201601731RA SG10201601731RA SG 10201601731R A SG10201601731R A SG 10201601731RA SG 10201601731R A SG10201601731R A SG 10201601731RA SG 10201601731R A SG10201601731R A SG 10201601731RA SG 10201601731R A SG10201601731R A SG 10201601731RA
- Authority
- SG
- Singapore
- Prior art keywords
- piperazine
- antipsychotic agents
- benzothiophene derivatives
- substituted benzothiophene
- substituted
- Prior art date
Links
- -1 Piperazine-substituted benzothiophene Chemical class 0.000 title 1
- 239000000164 antipsychotic agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532393P | 2011-09-08 | 2011-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201601731RA true SG10201601731RA (en) | 2016-04-28 |
Family
ID=46940565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601731RA SG10201601731RA (en) | 2011-09-08 | 2012-09-07 | Piperazine-substituted benzothiophene derivatives as antipsychotic agents |
| SG11201400148QA SG11201400148QA (en) | 2011-09-08 | 2012-09-07 | Piperazine- substituted benzothiophene derivatives as antipsychotic agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201400148QA SG11201400148QA (en) | 2011-09-08 | 2012-09-07 | Piperazine- substituted benzothiophene derivatives as antipsychotic agents |
Country Status (31)
| Country | Link |
|---|---|
| US (9) | US9260420B2 (enExample) |
| EP (1) | EP2753617B9 (enExample) |
| JP (1) | JP6193848B2 (enExample) |
| KR (1) | KR101998441B1 (enExample) |
| CN (1) | CN103781783B (enExample) |
| AR (1) | AR087809A1 (enExample) |
| AU (1) | AU2012305212B2 (enExample) |
| BR (1) | BR112014005235B1 (enExample) |
| CA (1) | CA2847339C (enExample) |
| CO (1) | CO6930362A2 (enExample) |
| CY (1) | CY1118753T1 (enExample) |
| DK (1) | DK2753617T3 (enExample) |
| EA (1) | EA028160B1 (enExample) |
| ES (1) | ES2572934T3 (enExample) |
| HR (1) | HRP20160824T2 (enExample) |
| HU (1) | HUE027746T2 (enExample) |
| IL (1) | IL231116B (enExample) |
| JO (1) | JO3227B1 (enExample) |
| MX (1) | MX359515B (enExample) |
| MY (1) | MY196864A (enExample) |
| PH (1) | PH12014500496A1 (enExample) |
| PL (1) | PL2753617T3 (enExample) |
| PT (1) | PT2753617T (enExample) |
| RS (1) | RS54894B9 (enExample) |
| SG (2) | SG10201601731RA (enExample) |
| SI (1) | SI2753617T1 (enExample) |
| SM (1) | SMT201600205B (enExample) |
| TW (1) | TWI568728B (enExample) |
| UA (1) | UA112993C2 (enExample) |
| WO (1) | WO2013035892A1 (enExample) |
| ZA (1) | ZA201401433B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JP2014196292A (ja) * | 2013-03-07 | 2014-10-16 | 大塚製薬株式会社 | 医薬 |
| CN104447723A (zh) * | 2014-11-28 | 2015-03-25 | 瑞阳制药有限公司 | 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法 |
| CN104829603A (zh) * | 2015-05-19 | 2015-08-12 | 杭州新博思生物医药有限公司 | A晶型依匹唑派盐酸盐及其制备方法 |
| WO2017162536A1 (en) | 2016-03-21 | 2017-09-28 | H. Lundbeck A/S | Vortioxetine prodrugs |
| PL233778B1 (pl) | 2016-07-19 | 2019-11-29 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu |
| CN109716411B (zh) * | 2016-09-08 | 2021-06-25 | 福特汽车公司 | 用以监测驾驶员的活动水平的方法和设备 |
| CN106699745A (zh) * | 2016-12-14 | 2017-05-24 | 上海博志研新药物技术有限公司 | 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用 |
| US20180265472A1 (en) * | 2017-03-17 | 2018-09-20 | Scinopharm Taiwan, Ltd. | Process for preparing aripiprazole lauroxil and intermediates thereof |
| CN107628999B (zh) * | 2017-10-25 | 2019-07-02 | 苏州华健瑞达医药技术有限公司 | 阿立哌唑十二烷酸酯的制备方法 |
| CN109988162A (zh) * | 2017-12-29 | 2019-07-09 | 武汉兴华智慧医药科技有限公司 | 一种依匹哌唑衍生物及其制备方法 |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| CN108947990A (zh) * | 2018-07-20 | 2018-12-07 | 成都苑东生物制药股份有限公司 | 一种苯并噻吩类化合物的制备方法 |
| PL3908570T3 (pl) * | 2019-01-11 | 2024-07-01 | Alar Pharmaceuticals Inc. | Embonian ketaminy i jego zastosowanie |
| TW202216676A (zh) | 2020-07-06 | 2022-05-01 | 美商塔朵根公司 | 用於心理疾病或心理強化的有益苯并噻吩組合物 |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| CN114044772A (zh) * | 2021-11-29 | 2022-02-15 | 浙江国邦药业有限公司 | 一种依匹哌唑合成方法及其中间体 |
| CN116410186B (zh) * | 2021-12-30 | 2025-03-04 | 上海现代药物制剂工程研究中心有限公司 | 依匹哌唑甲基脂肪酸酯及其制备方法 |
| CN116407539B (zh) * | 2021-12-30 | 2025-01-10 | 上海现代药物制剂工程研究中心有限公司 | 依匹哌唑甲基脂肪酸酯的用途 |
| WO2023186023A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州旺山旺水生物医药股份有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
| JP2023173950A (ja) * | 2022-05-27 | 2023-12-07 | 同仁医薬化工株式会社 | 経口液剤 |
| TW202438064A (zh) * | 2023-02-27 | 2024-10-01 | 日商大塚製藥股份有限公司 | 用於治療心理疾病之經哌𠯤取代之苯并噻吩 |
| JPWO2024228399A1 (enExample) | 2023-05-02 | 2024-11-07 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12923A (en) * | 2002-09-17 | 2006-10-13 | Warner Lambert Co | Heterocyclic substituted piperazines for the treatment of schizophrenia. |
| KR100842694B1 (ko) | 2002-12-27 | 2008-07-01 | 오쓰까 세이야꾸 가부시키가이샤 | 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제 |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US20050254575A1 (en) | 2004-05-12 | 2005-11-17 | Nokia Corporation | Multiple interoperability points for scalable media coding and transmission |
| DE102004031052A1 (de) | 2004-06-25 | 2006-01-12 | Bühler AG | System und Verfahren zur Mahlgut-Charakterisierung in einem Walzenstuhl |
| WO2006011246A1 (ja) | 2004-07-29 | 2006-02-02 | Magie Pression Co., Ltd. | ポリ乳酸糸で構成された布帛のプリーツ形成法およびプリーツ布帛 |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| WO2006111246A1 (de) | 2005-04-18 | 2006-10-26 | Loi Thermprocess Gmbh | Industrieofen |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| CA2937222C (en) * | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| US8431576B2 (en) * | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| EP2521711B1 (en) | 2010-01-07 | 2017-08-16 | Alkermes Pharma Ireland Limited | Quaternary ammonium salt prodrugs |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| US20120202823A1 (en) | 2010-12-23 | 2012-08-09 | Alkermes, Inc. | Multi-API Loading Prodrugs |
| HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
| JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
-
2012
- 2012-09-06 JO JOP/2012/0253A patent/JO3227B1/ar active
- 2012-09-07 US US14/343,579 patent/US9260420B2/en active Active
- 2012-09-07 EP EP12766485.2A patent/EP2753617B9/en active Active
- 2012-09-07 WO PCT/JP2012/073556 patent/WO2013035892A1/en not_active Ceased
- 2012-09-07 TW TW101132738A patent/TWI568728B/zh active
- 2012-09-07 DK DK12766485.2T patent/DK2753617T3/en active
- 2012-09-07 HU HUE12766485A patent/HUE027746T2/en unknown
- 2012-09-07 MX MX2014002254A patent/MX359515B/es active IP Right Grant
- 2012-09-07 ES ES12766485.2T patent/ES2572934T3/es active Active
- 2012-09-07 BR BR112014005235-2A patent/BR112014005235B1/pt active IP Right Grant
- 2012-09-07 PT PT127664852T patent/PT2753617T/pt unknown
- 2012-09-07 CA CA2847339A patent/CA2847339C/en active Active
- 2012-09-07 SI SI201230630A patent/SI2753617T1/sl unknown
- 2012-09-07 MY MYPI2014700554A patent/MY196864A/en unknown
- 2012-09-07 UA UAA201403486A patent/UA112993C2/uk unknown
- 2012-09-07 SG SG10201601731RA patent/SG10201601731RA/en unknown
- 2012-09-07 JP JP2014511630A patent/JP6193848B2/ja active Active
- 2012-09-07 AU AU2012305212A patent/AU2012305212B2/en active Active
- 2012-09-07 RS RS20160492A patent/RS54894B9/sr unknown
- 2012-09-07 PH PH1/2014/500496A patent/PH12014500496A1/en unknown
- 2012-09-07 SG SG11201400148QA patent/SG11201400148QA/en unknown
- 2012-09-07 EA EA201490585A patent/EA028160B1/ru not_active IP Right Cessation
- 2012-09-07 KR KR1020147009258A patent/KR101998441B1/ko active Active
- 2012-09-07 CN CN201280043980.2A patent/CN103781783B/zh active Active
- 2012-09-07 HR HRP20160824TT patent/HRP20160824T2/hr unknown
- 2012-09-07 PL PL12766485.2T patent/PL2753617T3/pl unknown
- 2012-09-07 AR ARP120103307A patent/AR087809A1/es not_active Application Discontinuation
-
2014
- 2014-02-24 IL IL231116A patent/IL231116B/en active IP Right Grant
- 2014-02-25 ZA ZA2014/01433A patent/ZA201401433B/en unknown
- 2014-04-03 CO CO14071857A patent/CO6930362A2/es unknown
-
2015
- 2015-12-29 US US14/982,807 patent/US9539252B2/en active Active
-
2016
- 2016-06-30 SM SM201600205T patent/SMT201600205B/it unknown
- 2016-07-04 CY CY20161100617T patent/CY1118753T1/el unknown
- 2016-11-23 US US15/359,809 patent/US20170071933A1/en not_active Abandoned
-
2017
- 2017-07-07 US US15/643,969 patent/US20180092907A1/en not_active Abandoned
-
2018
- 2018-07-12 US US16/033,749 patent/US20180318294A1/en not_active Abandoned
-
2019
- 2019-02-06 US US16/268,827 patent/US20190167672A1/en not_active Abandoned
- 2019-10-29 US US16/666,546 patent/US20200061056A1/en not_active Abandoned
-
2020
- 2020-06-09 US US16/896,329 patent/US20210052575A1/en not_active Abandoned
-
2022
- 2022-01-18 US US17/577,465 patent/US20230099694A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201401433B (en) | Piperazine-substituted benzothiophene derivatives as antipsychotic agents | |
| AP3336A (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
| SG10201601802YA (en) | Dispiropyrrolidine derivatives | |
| ZA201307119B (en) | Double-acylated glp-1 derivatives | |
| AP2013007043A0 (en) | Novel heterocyclic derivatives | |
| ZA201401884B (en) | New dihydroquinoline-2-one derivatives | |
| EP2709609A4 (en) | HETEROCYCLIC COMPOUNDS | |
| SG11201401937YA (en) | New aryl-quinoline derivatives | |
| ZA201307428B (en) | Thiazole derivatives | |
| IL247638B (en) | History of heteroaryl piperidine | |
| IL233001A0 (en) | New iso-ergoline histories | |
| SI2766342T1 (sl) | Derivati fenil-gvanidina | |
| ZA201308049B (en) | 3-ureidoisoquinolin-8-yl derivatives | |
| GB201107672D0 (en) | Ink | |
| GB201204960D0 (en) | Inks | |
| ZA201209319B (en) | Cyclopropyl-indole derivatives | |
| GB201100830D0 (en) | Printing composition | |
| GB201122030D0 (en) | Inks |